Pulmonary Complications of DAAs in HCV Treatment

This research paper explores the under-recognized yet clinically significant pulmonary complications associated with Direct-Acting Antivirals (DAAs) used in the treatment of Hepatitis C Virus (HCV) infection. While DAAs have revolutionized HCV therapy with high cure rates and improved safety profiles, emerging evidence suggests a spectrum of respiratory adverse events—from interstitial lung disease to exacerbation of pre-existing pulmonary conditions.